ES2755708T3 - Variantes Fc con funciones efectoras reducidas - Google Patents

Variantes Fc con funciones efectoras reducidas Download PDF

Info

Publication number
ES2755708T3
ES2755708T3 ES12735242T ES12735242T ES2755708T3 ES 2755708 T3 ES2755708 T3 ES 2755708T3 ES 12735242 T ES12735242 T ES 12735242T ES 12735242 T ES12735242 T ES 12735242T ES 2755708 T3 ES2755708 T3 ES 2755708T3
Authority
ES
Spain
Prior art keywords
region
variant
294del
amino acid
parent polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12735242T
Other languages
English (en)
Spanish (es)
Inventor
Alexandre Fontayne
Sylvie Jorieux
Céline Monnet-Mars
Philippe Mondon
Abdelhakim Kharrat
Khalil Bouayadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Application granted granted Critical
Publication of ES2755708T3 publication Critical patent/ES2755708T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES12735242T 2011-06-24 2012-06-25 Variantes Fc con funciones efectoras reducidas Active ES2755708T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305811.9A EP2537864B1 (en) 2011-06-24 2011-06-24 Fc variants with reduced effector functions
PCT/EP2012/062273 WO2012175751A2 (en) 2011-06-24 2012-06-25 Fc variants with reduced effector functions

Publications (1)

Publication Number Publication Date
ES2755708T3 true ES2755708T3 (es) 2020-04-23

Family

ID=45058478

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12735242T Active ES2755708T3 (es) 2011-06-24 2012-06-25 Variantes Fc con funciones efectoras reducidas

Country Status (8)

Country Link
US (1) US20140378663A1 (zh)
EP (2) EP2537864B1 (zh)
JP (1) JP6080844B2 (zh)
CN (2) CN103827142A (zh)
BR (1) BR112013033342A2 (zh)
CA (1) CA2840127C (zh)
ES (1) ES2755708T3 (zh)
WO (1) WO2012175751A2 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CA2943943C (en) * 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
BR112016022910A2 (pt) 2014-04-11 2017-10-17 Medimmune Llc anticorpos contra her2 biespecíficos
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
FR3024453B1 (fr) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
SG11201703332SA (en) 2014-11-10 2017-05-30 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
FR3034420A1 (fr) * 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
CN115304669A (zh) * 2016-06-08 2022-11-08 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
JP2020531002A (ja) * 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
FR3081328B1 (fr) * 2018-05-24 2021-01-01 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
CN113227135A (zh) 2018-12-28 2021-08-06 斯帕克斯治疗公司 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
CN111514291B (zh) * 2020-05-05 2023-05-09 华中科技大学同济医学院附属协和医院 红斑狼疮IgG在制备抑制骨质损坏药物中的应用
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN115322255A (zh) * 2022-04-25 2022-11-11 上海药明生物医药有限公司 一种优化的Fc变体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR951412A (fr) 1943-01-05 1949-10-25 Thomson Houston Comp Francaise Perfectionnements aux régulateurs de tension
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR20060067983A (ko) * 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
WO2009009103A2 (en) * 2007-07-10 2009-01-15 Medimmune, Llc CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants

Also Published As

Publication number Publication date
JP2014519836A (ja) 2014-08-21
EP2723770A2 (en) 2014-04-30
CA2840127C (en) 2020-02-18
CN103827142A (zh) 2014-05-28
EP2723770B1 (en) 2019-07-31
US20140378663A1 (en) 2014-12-25
EP2537864A1 (en) 2012-12-26
BR112013033342A2 (pt) 2017-01-31
CN107474138A (zh) 2017-12-15
WO2012175751A2 (en) 2012-12-27
EP2537864B1 (en) 2019-08-07
JP6080844B2 (ja) 2017-02-15
CA2840127A1 (en) 2012-12-27
WO2012175751A3 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
ES2755708T3 (es) Variantes Fc con funciones efectoras reducidas
US11629189B2 (en) Bispecific antibody for ICOS and PD-L1
JP6956083B2 (ja) Ｃｄ３とｃｄ３８とを結合するヘテロ二量体抗体
JP6840908B1 (ja) エフェクター機能が除去されたＩｇＧ１ Ｆｃ変異体
EP3889174A1 (en) Homodimer-type bispecific antibody against her2 and cd3 and use thereof
ES2746103T3 (es) Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas
ES2726625T3 (es) Variantes de Fc optimizadas
CN112351997B (zh) 与cd19结合的重链抗体
US20230340114A1 (en) Novel anti-lilrb4 antibodies and derivative products
CA3172641A1 (en) Masked il-12 cytokines and their cleavage products
TWI838621B (zh) 具有經修飾重鏈恆定區之多特異性重鏈抗體
TW201738270A (zh) 利用置換ｃｄｒ區胺基酸來改變抗體等電點的方法
US20230203161A1 (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
JP2015524387A (ja) 三重変異を有する二量体タンパク質
KR20140146040A (ko) 항체 변이체 및 그의 용도
EP3902832A2 (en) Anti-ctla4 antibodies and methods of use thereof
TW202235431A (zh) 腫瘤特異性可裂解連接子
JP2020535819A (ja) Ｃｄ３／ｃｄ３３二重特異性結合分子
TWI599577B (zh) Methods to alter the isoelectric point of antibodies using amino acid substitutions of CDR regions
BR122022022755A2 (pt) Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
WO2024089609A1 (en) Glycoengineered fc variant polypeptides with enhanced effector function
WO2022098910A1 (en) Icos antibodies for treatment of lymphomas